Policy update on Prostate Cancer Screening
Dear colleagues, dear friends,
The discussion on population-based PSA screening for early detection on prostate cancer is entering a new phase. After years of discouraging the use of PSA screening programmes at the national level, mortality rates for prostate cancer are increasing in different countries and more and more patients are diagnosed at locally-advanced or metastatic stages. Recent evidence, however, shows the efficacy of prostate cancer screening programmes. This was the reason for the European Association of Urology to develop a Policy Paper on structured, population-based PSA screening for prostate cancer, which was launched during the European Prostate Cancer Awareness Day at the European Parliament in Brussels last 22 January.
The event was well-attended by several European political influencers and aimed to reconsider PSA screening programmes at European level. With the upcoming European Parliamentary elections, we felt the time was right to get this topic on the political agenda and we are pleased to inform you that some important steps have been taken in the realisation of a European early detection programme for prostate cancer.
Based on the presented evidence by various experts during the EPAD meeting, the members of the “MEPs against Cancer” group (MAC) have confirmed that the efficacy of PSA screening for early detection of prostate cancer is clear and that action needs to be taken now. They will encourage fellow MEPs to put this topic on their agenda for the upcoming EU elections.
Furthermore, the Innovative Partnership for Action Against Cancer (IPAAC) was also committed to contributing to taking steps in the early detection and screening of prostate cancer. Their coordinator Dr. Tit Albreht confirmed the inclusion of population-based PSA screening in their Joint Action against Cancer as part of the European Commission’s Third Health Programme 2014–2020, similar to how this was achieved with screening programmes for breast, cervical and colorectal cancers.
After a long lobbying process, we are now seeing that our perseverance is paying off and the first results are becoming a reality. However, in order to make this happen at a European level, it is important to involve EU Member States, who in the end are responsible for health issues in their country, and their national representatives as well. We invite you to join our mission and we ask your support in engaging with the politicians responsible for healthcare in your country.
What can you do?
·Inform national politicians and MEPs from your country about the policy update on prostate cancer screening that will be part of the EU Joint Action, the Innovative Partnership for Action Against Cancer (IPAAC).
·Ask Member States to support European guidelines on prostate cancer screening.
·Present good practice on prostate cancer screening in your country to your national political influencers in order to secure necessary support and funding at the EU level.
If you are interested in actively participating in the introduction of population-based PSA screening for early detection on prostate cancer, please get in touch with Astrid Driessen-Venhorst (via email@example.com). We can assist in providing you with different materials and would like to discuss a joint strategy to make politicians in your country aware of the latest developments in PCa screening.
We look forward to hearing from you and jointly continuing our fight against prostate cancer.
With kindest regards,
Prof. Christopher Chapple Prof. Hein van Poppel
Secretary General EAU Adjunct Secretary General EAU - Executive Member Education
Hier vindt u enkele interessante presentaties:
- prof. H. Van Poppel: "Has the time come to reconsider PSA Screening for Prostate Cancer?"
- Michelle Battye - EAU EU Policy Coordinator: "Call to action"
- EAU-ESTRO-ESUR-SIOG "Guidelines on prostate cancer"